title: [Free radical processes in patients with the acute calculous cholecystitis].
abstract: The role of the free radical processes (FRP) is shown and objectified in the development of the acute calculous cholecystitis (ACC). It is revealed on the first day of hospitalization already. In catarrhal and phlegmonic ACC free radical processes changes apply mostly to the oxygen part of the oxidation process. The greatest imbalance of the FRP is registered in the gangrenous ACC. It appeared like decrease of the oxygen and activation of the lipid FRP disregulation. On the first day FRP changes refer to the oxygen part of the oxidation process only. Starts with a second day from the disease début changes in the lipid component of the oxidative stress join the disregulation process. It is proved by the decrease of the antiperoxidant activity of plasma and increase of malondialdehyde. Malondialdehyde level and its rate of rise serve as prognostic criteria of the course and outcome of disease. FRP changes correlate with the clinical presentations of disease. They last till the patient's discharge. The high efficiency of the energetic corrector reamberin in a dose of 400-800 ml was shown in patients with ACC.
authors.forename: M A
authors.initials: MA
authors.lastname: Khokonov
authors.forename: E V
authors.initials: EV
authors.lastname: Silina
authors.forename: V A
authors.initials: VA
authors.lastname: Stupin
authors.forename: T V
authors.initials: TV
authors.lastname: Gakhramanov
authors.forename: S B
authors.initials: SB
authors.lastname: Bolevich
authors.forename: N I
authors.initials: NI
authors.lastname: Men'shova
authors.forename: T G
authors.initials: TG
authors.lastname: Sinel'nikova
authors.forename: Z Z
authors.initials: ZZ
authors.lastname: Balkizov
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000975:Antioxidants / Q000008:administration & dosage / Q000009:adverse effects; D002763:Cholecystectomy; D041881:Cholecystitis, Acute / Q000000981:diagnostic imaging / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy*; D016903:Drug Monitoring; D005260:Female; D005609:Free Radicals / Q000378:metabolism*; D042882:Gallstones / Q000150:complications; D006801:Humans; D007262:Infusions, Intravenous; D050356:Lipid Metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008536:Meglumine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D008875:Middle Aged; D010084:Oxidation-Reduction / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects*; D013386:Succinates / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D000975:Antioxidants; D005609:Free Radicals; C549374:Reamberin; D013386:Succinates; D008315:Malondialdehyde; D008536:Meglumine